Literature DB >> 16143142

Defective DNA mismatch repair determines a characteristic transcriptional profile in proximal colon cancers.

Massimiliano di Pietro1, Jacob Sabates Bellver, Mirco Menigatti, Fridolin Bannwart, Annelies Schnider, Anna Russell, Kaspar Truninger, Josef Jiricny, Giancarlo Marra.   

Abstract

BACKGROUND & AIMS: Colon cancers with defective DNA mismatch repair (MMR) have peculiar molecular, pathologic, and clinical features, including high-level microsatellite instability, conspicuous lymphocytic infiltration, preferential location in the proximal colon, and better prognosis. Our aim was to characterize the transcriptional profile of this colon cancer subset.
METHODS: An oligonucleotide microarray containing 12,625 probes was used to evaluate gene expression in 25 proximal colon cancers, 10 samples of normal colon mucosa, and 14 colon cancer cell lines. Transcriptional profiles of MMR-deficient cancers and cell lines were compared with those of their MMR-proficient counterparts.
RESULTS: Unsupervised analysis of microarray data showed that MMR status exerts a predominant influence on the gene expression profile of proximal colon cancers. Hierarchical clustering divided the cancers into 2 groups corresponding almost perfectly with their MMR status. Supervised analysis identified numerous gene expression changes that represent a genetic signature of MMR-deficient colon cancers. Changes in genes involved in apoptosis and the immune response were consistent with the better prognosis of MMR-deficient cancers. In MMR-deficient cancers and cell lines, 4-1BBL, a crucial gene in the anti-tumor immune response, was, respectively, 2.4 and 6.0 times more expressed than in their MMR-proficient counterparts. This difference was confirmed by quantitative reverse-transcription polymerase chain reaction and flow cytometric assessment of 4-1BBL protein expression in colon cancer cell lines. Our analysis also showed novel possible gene targets of microsatellite instability.
CONCLUSIONS: MMR inactivation produces distinct changes in the cellular messenger RNA pool, which is consistent with a unique tumorigenesis pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16143142     DOI: 10.1053/j.gastro.2005.06.028

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  19 in total

1.  Instability of a dinucleotide repeat in the 3'-untranslated region (UTR) of the microsomal prostaglandin E synthase-1 (mPGES-1) gene in microsatellite instability-high (MSI-H) colorectal carcinoma.

Authors:  Durga Prasad Cherukuri; Joshua L Deignan; Kingshuk Das; Wayne W Grody; Harvey Herschman
Journal:  Mol Oncol       Date:  2015-03-05       Impact factor: 6.603

2.  Familial colorectal cancer: eleven years of data from a registry program in Switzerland.

Authors:  Michal Kovac; Endre Laczko; Ritva Haider; Josef Jiricny; Hansjakob Mueller; Karl Heinimann; Giancarlo Marra
Journal:  Fam Cancer       Date:  2011-09       Impact factor: 2.375

3.  Cleavage of E-cadherin by ADAM10 mediates epithelial cell sorting downstream of EphB signalling.

Authors:  Guiomar Solanas; Carme Cortina; Marta Sevillano; Eduard Batlle
Journal:  Nat Cell Biol       Date:  2011-07-31       Impact factor: 28.824

4.  Association between the expression levels of TAZ, AXL and CTGF and clinicopathological parameters in patients with colon cancer.

Authors:  Shu-Dong Zhang; Cian M McCrudden; Hiu-Fung Yuen; Ka Lai Leung; Wan-Jin Hong; Hang Fai Kwok
Journal:  Oncol Lett       Date:  2015-12-03       Impact factor: 2.967

5.  MutSbeta exceeds MutSalpha in dinucleotide loop repair.

Authors:  J Kantelinen; M Kansikas; M K Korhonen; S Ollila; K Heinimann; R Kariola; M Nyström
Journal:  Br J Cancer       Date:  2010-02-16       Impact factor: 7.640

6.  An A13 repeat within the 3'-untranslated region of epidermal growth factor receptor (EGFR) is frequently mutated in microsatellite instability colon cancers and is associated with increased EGFR expression.

Authors:  Ziqiang Yuan; Joongho Shin; Andrew Wilson; Sanjay Goel; Yi-He Ling; Naseem Ahmed; Higinio Dopeso; Minaxi Jhawer; Shannon Nasser; Cristina Montagna; Kenneth Fordyce; Leonard H Augenlicht; Lauri A Aaltonen; Diego Arango; Thomas K Weber; John M Mariadason
Journal:  Cancer Res       Date:  2009-09-29       Impact factor: 12.701

7.  Marine ω-3 Polyunsaturated Fatty Acid Intake and Risk of Colorectal Cancer Characterized by Tumor-Infiltrating T Cells.

Authors:  Mingyang Song; Reiko Nishihara; Yin Cao; Eunyoung Chun; Zhi Rong Qian; Kosuke Mima; Kentaro Inamura; Yohei Masugi; Jonathan A Nowak; Katsuhiko Nosho; Kana Wu; Molin Wang; Edward Giovannucci; Wendy S Garrett; Charles S Fuchs; Shuji Ogino; Andrew T Chan
Journal:  JAMA Oncol       Date:  2016-09-01       Impact factor: 31.777

8.  Chemoprevention with Cyclooxygenase and Epidermal Growth Factor Receptor Inhibitors in Familial Adenomatous Polyposis Patients: mRNA Signatures of Duodenal Neoplasia.

Authors:  Don A Delker; Austin C Wood; Angela K Snow; N Jewel Samadder; Wade S Samowitz; Kajsa E Affolter; Kenneth M Boucher; Lisa M Pappas; Inge J Stijleman; Priyanka Kanth; Kathryn R Byrne; Randall W Burt; Philip S Bernard; Deborah W Neklason
Journal:  Cancer Prev Res (Phila)       Date:  2017-11-06

9.  Colon cancer molecular subtypes identified by expression profiling and associated to stroma, mucinous type and different clinical behavior.

Authors:  Beatriz Perez-Villamil; Alejandro Romera-Lopez; Susana Hernandez-Prieto; Guillermo Lopez-Campos; Antonio Calles; Jose-Antonio Lopez-Asenjo; Julian Sanz-Ortega; Cristina Fernandez-Perez; Javier Sastre; Rosario Alfonso; Trinidad Caldes; Fernando Martin-Sanchez; Eduardo Diaz-Rubio
Journal:  BMC Cancer       Date:  2012-06-19       Impact factor: 4.430

10.  Effects of a Novel Thiadiazole Derivative with High Anticancer Activity on Cancer Cell Immunogenic Markers: Mismatch Repair System, PD-L1 Expression, and Tumor Mutation Burden.

Authors:  Sofia Sagredou; Panagiotis Dalezis; Eirini Papadopoulou; Maria Voura; Maria V Deligiorgi; Michail Nikolaou; Mihalis I Panayiotidis; George Nasioulas; Vasiliki Sarli; Dimitrios T Trafalis
Journal:  Pharmaceutics       Date:  2021-06-15       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.